Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Juvenile Macular Degeneration is an unprecedented group of inherited eye disorders that affect youngsters and young adults, mainly due to modern imagination and prescient loss. This situation, on the whole, goals the macula, a small place close to the middle of the retina answerable for sharp and central vision. JMD is characterized by its early onset, normally manifesting in youth or early life. While it constitutes a small part of typical macular degeneration cases, its effect on the more youthful population's nice lifestyles makes it a large difficulty. The rarity of JMD has triggered improved attention from medical and research groups. The market dynamics of JMD are influenced by improvements in diagnostic technology and developing awareness among healthcare specialists and the general public. Early detection performs a vital role in managing the situation, and as diagnostic gear enhances, more cases are being recognized, developing a demand for targeted healing procedures.
Genetic healing procedures represent a promising avenue within the JMD market, focused on the underlying genetic mutations liable for the situation. The improvement of gene-modifying technology and gene alternative remedies holds a huge ability for addressing the basic causes of JMD, imparting hope for more effective and customized treatment alternatives. Collaborations among pharmaceutical companies, studies establishments, and patient advocacy agencies are becoming increasingly prevalent within the JMD market. The purpose of these partnerships is to pool sources of percentage expertise and boost the development of novel treatment options. Regulatory bodies play a critical function in shaping the JMD market dynamics. As capacity healing procedures undergo scientific trials, regulatory approvals end up pivotal for market access.
The patient gets admission to rising remedies, and their affordability is an important consideration within the JMD market. The high fee of developing and manufacturing advanced treatments poses demanding situations in ensuring full-size accessibility. Striking stability among innovation and affordability is vital to address the needs of sufferers and promote market sustainability. Patient advocacy businesses make an extensive contribution to the JMD market dynamics by elevating attention, imparting support, and influencing research priorities. Their efforts no longer best empower sufferers and their households; however, they additionally make contributions to the overall understanding of the sickness, fostering collaborative surroundings for advancements in JMD care. The destiny of the JMD market holds promise as ongoing research sheds light on the genetic and molecular underpinnings of the disease. With growing expertise of its complexities, coupled with improvements in healing modalities, the market is poised for transformative changes, supplying the desire for improved effects and better great of lifestyles for individuals tormented by JMD.
Juvenile Macular Degeneration Market Highlights:
Juvenile Macular Degeneration Market Overview :
Juvenile Macular Degeneration (Stargardt Disease) Market Size was valued at USD 1.44 Billion in 2023. The Global Juvenile Macular Degeneration (Stargardt Disease) industry is projected to grow from USD 1.52 Billion in 2024 to USD 1.85 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.36% during the forecast period (2024 - 2032).
Juvenile macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, juvenile macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The market is mainly driven by factors such as the increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies. However, the high cost of treatment and lack of reimbursement is expected to restrain the growth of this market.
Market Dynamics
The rising prevalence of eye disorder and technological advancements in juvenile macular degeneration are some of the factors that drive the growth of the market. Juvenile macular degeneration is a rare inherited eye condition which affects the central area of the retina called the macula, also known as fundus flavimaculatus. It affects about 1 in 10,000 people and is sometimes called juvenile macular dystrophy since it tends to first appear between the ages of 10 to 20 although visual impairment may not be apparent until as late as ages 30 to 40. Juvenile macular degeneration disease causes parts of the macula to stop working, leading to problems with central vision, detailed vision, and sometimes with color perception. The major driving factors for the global juvenile macular degeneration market are increasing the prevalence of eye disorders, development of new drugs, and therapies, and emerging government policies. However, lack of awareness and no treatment option for juvenile macular dystrophy may hamper the market growth.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Size, by Diagnosis, 2016 and 2027 (USD Million) 
Source: MRFR Analysis
Segmentation
The global juvenile macular degeneration (Stargardt disease) market has been segmented into diagnosis, management, and end user. Based on the diagnosis, the market has been segregated into fluorescein angiography (FA), fundus autofluorescence (FAF), optical coherence tomography (OCT), and electroretinography (ERG). The FA segment accounted for a market value of USD 270.110 million in 2016. Based on management, the market has been segregated into magnifying spectacles, magnifiers, and reading telescopes. The global juvenile macular degeneration (Stargardt disease) market on the basis of end-user is divided into hospital & eye clinics, and research & academic institutes.
Key Players
The prominent players in the global juvenile macular degeneration (Stargardt disease) market are Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain).
Some of the key strategies followed by the players operating in the global juvenile macular degeneration (Stargardt disease) market were innovation, product development, acquisition, mergers, and expansion.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Region, 2016 (%) 
Source: MRFR Analysis
Regional Analysis
The global juvenile macular degeneration (Stargardt disease) market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Europe accounted for the significant share in the market for juvenile macular degeneration. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region. Europe held the most significant market share of 32.7 % in 2016.
Americas is estimated to be the second-largest market. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and rapidly changing healthcare sector. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
- In November 2017, Astellas Pharma Inc launched “Repatha” a human monoclonal antibody for the treatment of hypercholesterolemia.
- In December 2017, Sanofi acquired Protein Science company in order to expand its product portfolio.
- In January 2017, Acucela Inc received orphan drug approval for treatment of Stargardt disease. Hence this product approval will help the company to increase its revenue in the future as very few drugs are available for the treatment of Stargardt disease.
Market Segmentation
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis
- Fluorescein Angiography (FA)
- Fundus Autofluorescence (FAF)
- Optical Coherence Tomography (OCT)
- Electroretinography (ERG)
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Management
- Magnifying Spectacles
- Magnifiers
- Reading telescopes
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End-User
- Hospital & Eye Clinics
- Research & Academic Institutes
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
Intended Audience
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
- Contract research organizations
- Pharmaceutical companies
- Medical research laboratories
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
